Is BXRXQ or XYLD a better dividend investment in 2026?

BXRXQ currently yields 20000000.00% with a 5% 5-year dividend growth rate. XYLD yields 10.98% with 0.5% growth. The better choice depends on your goal: BXRXQ offers higher current income.

What is the dividend yield difference between BXRXQ and XYLD?

BXRXQ has a forward dividend yield of 20000000.00% ($2.00/share annually). XYLD yields 10.98% ($4.30/share annually). The yield gap is 19999989.02 percentage points.

Home › Compare › BXRXQ vs XYLD

BXRXQ vs XYLD: Dividend Comparison 2026

BXRXQ yields 20000000.00% · XYLD yields 10.98%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 BXRXQ wins by $4.875981653489057e+49M in total portfolio value

INVESTMENT

TIME HORIZON10 years

BXRXQ

● Live price

20000000.00%

Share price

$0.00

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$4.875981653489057e+49M

Annual income

$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00

Full BXRXQ calculator →

XYLD

Global X S&P 500 Covered Call ETF

● Live price

10.98%

Share price

$39.13

Annual div

$4.30

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.3K

Annual income

$3,219.02

Full XYLD calculator →

Portfolio growth — BXRXQ vs XYLD

📍 BXRXQ pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	BXRXQ	XYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, BXRXQ + XYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

BXRXQ pays

XYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BXRXQ

Annual income on $10K today (after 15% tax)

$1,700,000,000.00/yr

After 10yr DRIP, annual income (after tax)

$41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr

XYLD

Annual income on $10K today (after 15% tax)

$933.63/yr

After 10yr DRIP, annual income (after tax)

$2,736.17/yr

At 15% tax rate, BXRXQ beats the other by $41,445,436,407,424,570,000,000,000,000,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BXRXQ + XYLD for your $10,000?

BXRXQ: 50%XYLD: 50%

100% XYLD50/50100% BXRXQ

Portfolio after 10yr

$2.4379908267445285e+49M

Annual income

$24,379,668,474,955,630,000,000,000,000,000,000,000,000,000,000,000,000,000.00/yr

Blended yield

100.00%

📊

Analyst Conviction Gap

Where Wall Street is split right now

BXRXQ

Analyst Ratings

Hold

Consensus: Hold

Altman Z

-17.4

Piotroski

2/9

XYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BXRXQ buys

XYLD buys

No recent congressional trades found for BXRXQ or XYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricBXRXQXYLD

Forward yield	20000000.00% ✓	10.98%
Annual dividend / share	$2.00	$4.30 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$4.875981653489057e+49M	$25.3K ✓
Annual income after 10y	$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00 ✓	$3,219.02
Total dividends collected	$4.875978515990276e+49M	$19.6K ✓
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: BXRXQ vs XYLD ($10,000, DRIP)

Year	BXRXQ Portfolio	BXRXQ Income/yr	XYLD Portfolio	XYLD Income/yr	Gap
1← crossover	$2,000,010,700	$2,000,000,000.00	$10,818	$1,098.39	+$2000.00M → BXRXQ
2	$373,835,915,712,384	$373,833,775,700,934.50	$11,738	$1,222.51	+$373835915.70M → BXRXQ
3	$65,304,953,364,964,970,000	$65,304,553,360,535,160,000.00	$12,774	$1,364.64	+$65304953364964.95M → BXRXQ
4	$10,661,728,832,755,500,000,000,000	$10,661,658,956,455,399,000,000,000.00	$13,944	$1,527.86	+$10661728832755499008.00M → BXRXQ
5	$1,626,767,783,781,495,000,000,000,000,000	$1,626,756,375,731,643,800,000,000,000,000.00	$15,270	$1,715.87	+$1.626767783781495e+24M → BXRXQ
6	$231,974,330,054,625,100,000,000,000,000,000,000	$231,972,589,413,096,470,000,000,000,000,000,000.00	$16,775	$1,933.09	+$2.319743300546251e+29M → BXRXQ
7	$30,915,106,403,922,057,000,000,000,000,000,000,000,000	$30,914,858,191,388,900,000,000,000,000,000,000,000,000.00	$18,490	$2,184.87	+$3.0915106403922057e+34M → BXRXQ
8	$3,850,507,985,839,278,000,000,000,000,000,000,000,000,000,000	$3,850,474,906,675,425,000,000,000,000,000,000,000,000,000,000.00	$20,450	$2,477.63	+$3.8505079858392777e+39M → BXRXQ
9	$448,210,261,035,314,200,000,000,000,000,000,000,000,000,000,000,000	$448,206,140,991,769,400,000,000,000,000,000,000,000,000,000,000,000.00	$22,697	$2,819.19	+$4.4821026103531426e+44M → BXRXQ
10	$48,759,816,534,890,570,000,000,000,000,000,000,000,000,000,000,000,000,000	$48,759,336,949,911,260,000,000,000,000,000,000,000,000,000,000,000,000,000.00	$25,280	$3,219.02	+$4.875981653489057e+49M → BXRXQ

BXRXQ vs XYLD: Complete Analysis 2026

BXRXQ — Stock

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. On February 22, 2024, Baudax Bio, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Eastern District of Pennsylvania.

Full BXRXQ Calculator →

XYLD — ETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →

📬

Get this BXRXQ vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BXRXQ vs SCHD BXRXQ vs JEPI BXRXQ vs O BXRXQ vs KO BXRXQ vs MAIN BXRXQ vs QYLD BXRXQ vs JEPQ BXRXQ vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.